Sex-based disparities in cardiovascular outcomes: real-world evidence following chimeric antigen receptor T-cell therapy. [PDF]
Bahar AR +6 more
europepmc +1 more source
High versus low baseline CAR‐HEMATOTOX scores were associated with poorer safety and efficacy outcomes in patients with R/R B‐NHL who received odronextamab in the ELM‐1 and ELM‐2 studies. The CAR‐HEMATOTOX score may provide a readily available measure for identifying patients at risk of inferior clinical outcomes with odronextamab treatment.
Matthew Matasar +9 more
wiley +1 more source
Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug. [PDF]
Schenk HCM +8 more
europepmc +1 more source
Sweet-like syndrome secondary to chimeric antigen receptor T-cell therapy for multiple myeloma: a case report. [PDF]
Ouyang X +5 more
europepmc +1 more source
Summary Comprehensive genome and transcriptome profiling can inform the diagnosis, prognosis and management of relapsed/refractory (R/R) solid malignancies, yet its integration into clinical care has lagged despite strong biological rationale. We evaluated the clinical utility of whole genome and transcriptome analysis (WGTA) in 65 patients (37 ...
Kathleen Wee +24 more
wiley +1 more source
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma. [PDF]
Sharp J +13 more
europepmc +1 more source
Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study. [PDF]
Xu Y +5 more
europepmc +1 more source
Late Complications After European Medicines Agency-Approved Chimeric Antigen Receptor T-Cell Therapy in Hematological Malignancies: A Scoping Review. [PDF]
Eisenmann M, Zhu Z, Arndt V, Thong MSY.
europepmc +1 more source
Advancements in delivery systems for in vivo chimeric antigen receptor T-cell therapy in urological diseases. [PDF]
Li Y, Zhang W, Tang D.
europepmc +1 more source

